BridgeBio Oncology Therapeutics, Inc. Logo

BridgeBio Oncology Therapeutics, Inc.

Clinical-stage biopharma developing inhibitors for genetically driven cancers.

BBOT | US

Overview

Corporate Details

ISIN(s):
KYG4444H1011
LEI:
Country:
United States of America
Address:
256 E. GRAND AVENUE, SUITE 104, 94080 SOUTH SAN FRANCISCO

Description

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops a pipeline of novel, bioavailable small molecule inhibitors designed to treat patients with RAS-dependent cancers and other malignancies with clear genetic drivers. Its core strategy centers on inhibiting active RAS, aiming to create transformative medicines that advance beyond current therapeutic approaches. BBOT was launched to accelerate the development of its parent company's precision oncology portfolio.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all BridgeBio Oncology Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BridgeBio Oncology Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BridgeBio Oncology Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CHOONG ANG VACCINE LABORATORY Logo
Develops and manufactures vaccines, pharmaceuticals, and feed additives for animals.
South Korea
072020
CHOSA Oncology AB Logo
Develops diagnostics and therapeutics for platinum-based chemotherapy.
Sweden
CHOSA
CHUGAI PHARMACEUTICAL CO., LTD. Logo
A research-driven pharmaceutical company developing innovative medical products.
Japan
4519
CHUKYOIYAKUHIN CO.,LTD. Logo
Offers health products and pharmaceuticals via a direct-to-home placement service.
Japan
4558
Cidara Therapeutics, Inc. Logo
Develops targeted immunotherapies and anti-infectives for serious diseases.
United States of America
CDTX
Cinclus Pharma Holding AB Logo
Clinical-stage pharma company developing a PCAB for gastric acid-related diseases.
Sweden
CINPHA
Cingulate Inc. Logo
A clinical-stage biopharma firm developing treatments for ADHD and anxiety.
United States of America
CING
CITIUS ONCOLOGY, INC. Logo
Biopharmaceutical company developing and commercializing targeted oncology therapies.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
A late-stage biopharmaceutical company developing and commercializing critical care products.
United States of America
CTXR
CKD Bio Corp. Logo
Develops APIs, intermediates, and probiotics using fermentation and synthesis.
South Korea
063160

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.